In addition, several studies [9, 10] suggested that immune checkpoint inhibitors (ICIs) have some clinical effectiveness in NSCLC patients with high programmed death ligand 1 (PD-L1) expression with poor PS. This evidence concerns the gene CD274 and non-small cell lung carcinoma.